To read the full story, subscribe or sign in.

MD Anderson Cancer Center, Radiopharm launch JV for radiopharmaceuticals

Sep. 20, 2022

The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Ltd. have launched Radiopharm Ventures LLC, a joint venture (JV) that will develop radiopharmaceutical therapies for cancer. Radiopharm Theranostics owns 51% of shares in the new entity, while MD Anderson owns 49%.

BioWorld Asia Deals and M&A Drug resistance Joint venture Cancer Diagnostics Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for Nov. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 13, 2025.

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld Science

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...